GRK6-IN-2

CAS No. 2677786-27-3

GRK6-IN-2( —— )

Catalog No. M35570 CAS No. 2677786-27-3

GRK6-IN-2 is a potent G protein-coupled receptor kinase 6 (GRK6) inhibitor with potential antitumor activity.GRK6-IN-2 has been studied in multiple myeloma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 92 Get Quote
10MG 155 Get Quote
25MG 296 Get Quote
50MG 457 Get Quote
100MG 672 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GRK6-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    GRK6-IN-2 is a potent G protein-coupled receptor kinase 6 (GRK6) inhibitor with potential antitumor activity.GRK6-IN-2 has been studied in multiple myeloma.
  • Description
    GRK6-IN-2 (compound 10a) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC50 of 120 nM. GRK6 is a critical kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-2 has the potential for the research of multiple myeloma.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    GRK (GPCRK)
  • Recptor
    GRK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2677786-27-3
  • Formula Weight
    376.43
  • Molecular Formula
    C21H21FN6
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?Methanol : ≥ 125 mg/mL (332.07 mM)DMSO : ≥ 100 mg/mL (265.65 mM)
  • SMILES
    CCc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cc3)nc3ccccc23)n[nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Uehling DE, et al. Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma [published correction appears in J Med Chem. 2022 Jan 13;65(1):886-887]. J Med Chem. 2021;64(15):11129-11147.?
molnova catalog
related products
  • PEN (human)

    Endogenous peptide GPR83 agonist. ProSAAS-derived neuropeptide.

  • GRK6-IN-1

    GRK6-IN-1 (compound 18) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC50 of 120 nM, and has potential for study in multiple myeloma.

  • GRK2i

    GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. Corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist.